| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/22/2003 | EP1276457A1 A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1181029B1 Balsam for the treatment of surface burns and chafing rashes |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1030835B1 Urea derivatives and their use as integrin inhibitors |
| 01/22/2003 | EP0865339B1 Metalloproteinase inhibitors |
| 01/22/2003 | EP0828728B1 Phenyl dihydrobenzofuranes |
| 01/22/2003 | CN1392776A Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production |
| 01/22/2003 | CN1391951A Burn paste and its preparing method |
| 01/22/2003 | CN1391950A Acne clearing liquid |
| 01/22/2003 | CN1391946A Saussurea involucrata liquid for relaxing yin |
| 01/22/2003 | CN1391944A External use medicine |
| 01/22/2003 | CN1391925A Formula acne treating medicine and preparing method |
| 01/22/2003 | CN1391920A Medicine for treating dermatitis linked with leg ulcer |
| 01/22/2003 | CN1391880A Electric moxibustion instrument |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/21/2003 | US6509466 Reacting 17 beta-(alkoxycarbonyl)-3-one-4-aza-steroid with lithium tert-butylamide in an organic solvent |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509376 Utilization of dialkyfumarates |
| 01/21/2003 | US6509369 Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids |
| 01/21/2003 | US6509368 Use of catechol derivatives as proteinase inhibitors |
| 01/21/2003 | US6509364 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2α antagonists |
| 01/21/2003 | US6509357 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/21/2003 | US6509353 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509346 Chemokine receptor antagonists and methods of use therefor |
| 01/21/2003 | US6509318 TGF-B inhibitors and methods |
| 01/21/2003 | US6509177 Cultivating on a medium comprising at least one organic nitrogen or carbon source, in submerged aerated conditions, a Pseudomonas bacterium strain capable of the biosynthesis of pseudomonic acid A |
| 01/21/2003 | US6509165 Detecting the ability of proinsulin peptide to preferentially stimulate the T-cells of diabetic subjects by measuring the ability of the T-cells to proliferate or ability of the T-cells to produce cytokines |
| 01/21/2003 | US6509042 Anti viral composition |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6509014 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/17/2003 | CA2407295A1 Transgenic non-human mammal |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004527A2 Novel neurotrophic factors |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004497A1 Novel heterocyclic compound |
| 01/16/2003 | WO2003004495A1 Novel immunomodulating compounds |
| 01/16/2003 | WO2003004493A1 Novel compounds, their preparation and use |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004478A1 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) |
| 01/16/2003 | WO2003004475A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004472A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004098A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | WO2003004061A1 Uv-screening peptide-flavonoid conjugates |
| 01/16/2003 | WO2003004046A2 Use of xaa-pro peptidases for the treatment of substance p-related disorders |
| 01/16/2003 | WO2003004043A1 Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue |
| 01/16/2003 | WO2003004023A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives |
| 01/16/2003 | WO2003004017A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones |
| 01/16/2003 | WO2003004013A1 Wound treatment agent |
| 01/16/2003 | WO2003004010A1 Carbonylamino derivatives useful for obtaining immune regulation |
| 01/16/2003 | WO2003003997A2 Use of hops or hop-malt extracts in cosmetic or dermatological preparations |
| 01/16/2003 | WO2003003992A2 Hair lotion stimulating hair growth |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003971A2 Use of antidiabetics for making a medicine with cicatrizing effect |
| 01/16/2003 | WO2003003833A1 Antiviral composition and treatment method |
| 01/16/2003 | WO2002096221A3 Skin diet |
| 01/16/2003 | WO2002085387A3 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
| 01/16/2003 | WO2002085386A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/16/2003 | WO2002085385A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 01/16/2003 | WO2002050034A3 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002026782A3 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 01/16/2003 | WO2002022171A3 Pharmaceutical composition having specific water activity |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2002010406A3 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001060778A3 Aspirin-triggered lipid mediators |
| 01/16/2003 | US20030013875 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 01/16/2003 | US20030013850 Antiinflammatory agents |
| 01/16/2003 | US20030013770 Aminobenzophenones as inhibitors of il 1b and tnf |
| 01/16/2003 | US20030013758 Wound healing agents; brain disorders; cardiovascular disorders; sleep disorders |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013744 3,4-diaryl thiophenes and analogs thereof having use as anti-inflammatory agents |
| 01/16/2003 | US20030013742 Antiinflammatory agents; skin disorders |
| 01/16/2003 | US20030013734 Skin disorders, immunology diseases, wound healing agents, antiulcer agents |
| 01/16/2003 | US20030013723 Novel urokinase inhibitors |
| 01/16/2003 | US20030013718 Phthalazine derivatives for treating inflammatory diseases |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013704 Adamantane derivatives |
| 01/16/2003 | US20030013691 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/16/2003 | US20030013682 Heparins; antiutmor agents |
| 01/16/2003 | US20030013652 Releasing moderators for inflammation |
| 01/16/2003 | US20030012828 Topical medicine and process and apparatus for making same |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012818 Bioactive molecule that is a non-glycosylated member of the cystine knot growth factor superfamily is physically entrapped in the polymeric matrix. |
| 01/16/2003 | US20030012803 E.g., ethyl 3-methyl-5-(,5,8,8-tetra-methyl-5,6,7,8-tetra-hydronaphthalen-2 -ylselenyl)pent-2-en-4-ynoate; dermatological, rheumatic, respiratory, cardiovascular and ophthalmological uses as well as cosmetic uses |
| 01/16/2003 | US20030012793 Purified complex of heat shock protein noncovalently bound to a molecule. |
| 01/16/2003 | US20030012784 Methods for treatment of inflammatory diseases |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012781 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |